The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Directors

1 Jul 2013 09:41

RNS Number : 2542I
Akers Biosciences, Inc.
01 July 2013
 



 

1 July 2013

 

 

Akers Biosciences, Inc.

 

("ABI" or the "Company")

 

Appointment of Non-Executive Directors

 

Akers Biosciences, Inc (AIM: AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that Gavin Moran and Thomas Knox will be appointed to the board as Non-Executive Directors with effect from 1 July 2013.

 

Mr Moran, aged 43, is an Irish national who has previously worked for Shell International in Shell Chemicals, Marketing, Finance and Shell International Trading. He then held a Trading role as a beneficial shareholder at Trafigura, a leading international commodities trading and logistics company based in Amsterdam and then a Trading role as a beneficial shareholder at Sono International based in London. Mr Moran is indirectly interested through Chubeworkx Guernsey Limited, in which he holds a 31.69 per cent. shareholding, 80 million common shares in the Company, which represents 28.70 per cent of the Company's shares and 24.30 per cent. of the Company's voting rights.

 

Mr Knox, aged 72, is a Philadelphia, Pennsylvania-based businessman who has owned, managed, and ultimately sold multiple profitable companies in the software, banking, and health insurance industries including Disc Systems, Inc., Crusader Bank, Gimco International, Kasser Industries and Fidelity Insurance Group. He also served as Chief Executive Officer for United HealthCare of Pennsylvania and served as Special Deputy Rehabilitator & Chief Executive Officer of Fidelity Mutual Life Insurance Co., Pennsylvania's 5th largest insurer. He currently holds 30 million common shares and 10 million preference shares, which represents 10.76 per cent of the Company's shares and 28.78 per cent. of the Company's voting rights.

 

Raymond F. Akers, Executive Chairman of ABI commented, "It gives me great pleasure to welcome Gavin and Thomas to our Board. They have both invested in the company in the past year and bring with them expertise and experience, which will help move the company forward in the future. My colleagues and I are very much looking forward to our working together."

Further information concerning Mr Moran

Gavin Edwin David Moran's directorships (current and within the previous 5 years) are as follows:

 

Current: None

 

Past: None

 

Further information concerning Mr Knox

 

Thomas James Knox, a Chartered Life Underwriter (CLU) and Chartered Financial Consultant (ChFC), has been involved in Philadelphia politics having held the position of Deputy Mayor for the Office of Management and Productivity. Mr Knox is the Chief Executive Officer of Knox Consulting Group, Knox Family Loan Company and INDECS Corp.

Thomas James Knox's directorships (current and within the previous 5 years) are as follows:

 

Current: Knox Consulting Group

Knox Family Loan Company

INDECS Corp

Historic Philadelphia, Inc.

Newman Wine and Spirit Company

ORB Automotive based in Shenzhen, China

 

Past: None

 

There is no further information required relating to Thomas J. Knox or Gavin E.D. Moran to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

 

Enquiries:

Thomas A. Nicolette, President and CEO

Tel. +1 856 848 8698

Antony Legge / James Thomas

Daniel Stewart (Nomad and Broker)

 

 

 

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

End

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVFLBBXDFXBBK
Date   Source Headline
22nd Nov 200512:00 pmRNSHolding(s) in Company
15th Nov 20055:22 pmRNSHolding(s) in Company
14th Nov 20057:01 amRNSChange of Adviser
3rd Nov 20054:50 pmRNSIssue of Equity
17th Oct 20056:00 amPRNAdditional Listing
12th Oct 20055:17 pmRNSHolding(s) in Company
5th Oct 20056:00 amPRNTrading and Financing Update
27th Sep 20056:00 amPRNInterim Results
19th Sep 20056:00 amPRNNotice of Results
9th Sep 20056:00 amPRNSuccessful Outcome Of Litigation
5th Sep 20056:00 amPRNRe Distribution Agreement
26th Jul 20056:00 amPRNBusiness Update
1st Jul 200512:39 pmRNSIssue of Shares
30th Jun 200511:44 amRNSAnnual Report and Accounts
27th Jun 20056:00 amPRNUK Distribution Update
23rd Jun 20053:12 pmRNSIssue of Equity
22nd Jun 20054:19 pmRNSIssue of Equity
27th May 20057:00 amRNSIssue of Shares
12th May 200512:13 pmRNSIssue of Shares
28th Apr 20056:00 amPRNFDA Product Clearance
27th Apr 200512:37 pmRNSIssue of Equity
27th Apr 200510:32 amRNSDirector Shareholding
12th Apr 20055:49 pmRNSIssue of Equity
12th Apr 20056:00 amPRNFinal Results
14th Mar 20057:00 amPRNFinancing Agreement
1st Mar 20057:00 amPRNFDA Review On Akers Product
22nd Feb 20057:00 amPRNRe. Distribution Agreement
16th Feb 20055:22 pmRNSIssue of Equity
14th Feb 20057:00 amPRNRe Agreement
26th Jan 20054:28 pmRNSIssue of Equity
14th Jan 20057:00 amPRNTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.